loading
Schlusskurs vom Vortag:
$4.76
Offen:
$4.81
24-Stunden-Volumen:
280.19K
Relative Volume:
0.60
Marktkapitalisierung:
$282.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-5.4944
EPS:
-0.89
Netto-Cashflow:
$-30.67M
1W Leistung:
+14.99%
1M Leistung:
-11.21%
6M Leistung:
+24.62%
1J Leistung:
+101.23%
1-Tages-Spanne:
Value
$4.66
$5.005
1-Wochen-Bereich:
Value
$4.09
$5.12
52-Wochen-Spanne:
Value
$2.43
$6.5476

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Firmenname
Aldeyra Therapeutics Inc
Name
Telefon
781-761-4904
Name
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Mitarbeiter
9
Name
Twitter
@aldeyraaldx
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ALDX's Discussions on Twitter

Vergleichen Sie ALDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ALDX 4.92 282.86M 0 -44.80M -30.67M -0.89
VRTX 449.86 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.01 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.92 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.88 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.22 24.89B 3.30B -501.07M 1.03B 11.54

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-04-03 Hochstufung Oppenheimer Perform → Outperform
2024-04-02 Fortgesetzt H.C. Wainwright Buy
2022-04-27 Fortgesetzt H.C. Wainwright Buy
2021-02-08 Eingeleitet H.C. Wainwright Buy
2020-12-16 Eingeleitet Berenberg Buy
2020-10-30 Eingeleitet Jefferies Buy
2020-10-16 Eingeleitet BTIG Research Buy
2020-09-22 Eingeleitet Alliance Global Partners Buy
2020-05-12 Eingeleitet Oppenheimer Outperform
2018-12-04 Eingeleitet Citigroup Buy
2018-09-26 Bestätigt Cantor Fitzgerald Overweight
2018-09-13 Eingeleitet Janney Buy
2018-01-26 Eingeleitet Seaport Global Securities Buy
2016-09-26 Eingeleitet H.C. Wainwright Buy
2016-07-01 Eingeleitet Stifel Buy
2015-07-01 Eingeleitet Canaccord Genuity Buy
2015-03-25 Eingeleitet Chardan Capital Markets Buy
2015-03-20 Bestätigt H.C. Wainwright Buy
2014-11-18 Eingeleitet H.C. Wainwright Buy
2014-06-19 Eingeleitet Aegis Capital Buy
Alle ansehen

Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten

pulisher
05:44 AM

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

05:44 AM
pulisher
Nov 20, 2024

Top US Penny Stocks To Watch In November 2024 - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye D - GuruFocus.com

Nov 19, 2024
pulisher
Nov 19, 2024

5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com

Nov 19, 2024
pulisher
Nov 18, 2024

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St

Nov 14, 2024
pulisher
Nov 14, 2024

Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 13, 2024

Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR

Nov 13, 2024
pulisher
Nov 12, 2024

Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Nov 12, 2024
pulisher
Nov 08, 2024

(ALDX) Trading Advice - Stock Traders Daily

Nov 08, 2024
pulisher
Oct 31, 2024

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

(ALDX) Long Term Investment Analysis - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR

Oct 21, 2024
pulisher
Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart

Oct 21, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024
pulisher
Oct 21, 2024

Aldyera therapeutics director Nancy Miller-Rich buys $10,446 in stock - Investing.com

Oct 21, 2024
pulisher
Oct 17, 2024

(ALDX) Investment Analysis - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 12, 2024

Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 12, 2024
pulisher
Oct 08, 2024

Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR

Oct 08, 2024
pulisher
Oct 07, 2024

(ALDX) Proactive Strategies - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals

Oct 03, 2024
pulisher
Oct 03, 2024

Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine

Oct 03, 2024
pulisher
Oct 03, 2024

Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada

Oct 03, 2024
pulisher
Oct 03, 2024

Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia

Oct 03, 2024
pulisher
Oct 03, 2024

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch

Oct 03, 2024
pulisher
Oct 03, 2024

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan

Oct 03, 2024
pulisher
Oct 02, 2024

Aldeyra Therapeutics extends loan agreement terms - Investing.com India

Oct 02, 2024
pulisher
Oct 02, 2024

Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK

Oct 02, 2024
pulisher
Oct 02, 2024

Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com

Oct 02, 2024
pulisher
Oct 01, 2024

Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News

Oct 01, 2024
pulisher
Sep 30, 2024

Aldeyra Therapeutics Inc (ALDX) rating upgrades by Oppenheimer - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Buys 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Sep 30, 2024
pulisher
Sep 26, 2024

(ALDX) Trading Signals - Stock Traders Daily

Sep 26, 2024

Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):